Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453882 | 0.89 | HRH3 (0.49) | HRH3HSD17B10HTR1AHTR7LMNA | |
| SCHEMBL7130414 | 0.87 | HSD17B10 (0.64) | TSHRALOX15HSD17B10GLASMN1; SMN2 | |
| SCHEMBL13419165 | 0.84 | HRH3 (0.49) | HRH3HTR1AHTR7POLBALDH1A1 | |
| SCHEMBL14471180 | 0.84 | HRH3 (0.46) | HRH3SMN1; SMN2HTR1AHTR7ALDH1A1 | |
| SCHEMBL13043899 | 0.84 | HSD17B10 (0.73) | HRH3TSHRALOX15HSD17B10LMNA | |
| SCHEMBL7130429 | 0.83 | GLA (0.62) | TSHRALOX15HSD17B10GLASMN1; SMN2 | |
| SCHEMBL13043924 | 0.81 | HRH3 (0.44) | HRH3HSD17B10SMN1; SMN2HTR1AHTR7 | |
| SCHEMBL14627467 | 0.81 | TSHR (0.53) | TSHRALOX15HSD17B10GLASMN1; SMN2 | |
| SCHEMBL10092693 | 0.79 | ALDH1A1 (0.50) | HRH3GLASMN1; SMN2ALDH1A1 | |
| SCHEMBL26494077 | 0.79 | HRH3 (0.42) | HRH3HTR1AHTR7POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829567-B2 | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-09 | — | — | US | disclosed |
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | IMPA1, IMPDH1, IPO5 | HRH3 1002/4885TSHR 4307/4885ALOX15 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.